BioCardia (NASDAQ:BCDA) Posts Earnings Results

BioCardia (NASDAQ:BCDAGet Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,208.76%. The company had revenue of $0.06 million for the quarter. During the same quarter last year, the business earned ($0.17) earnings per share.

BioCardia Price Performance

BioCardia stock opened at $0.40 on Friday. BioCardia has a 1-year low of $0.32 and a 1-year high of $2.92. The firm’s 50 day simple moving average is $0.39 and its 200 day simple moving average is $0.50.

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

See Also

Earnings History for BioCardia (NASDAQ:BCDA)

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.